Page last updated: 2024-09-04

moxifloxacin and Koch's Disease

moxifloxacin has been researched along with Koch's Disease in 121 studies

Research

Studies (121)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (0.83)	18.2507
2000's	25 (20.66)	29.6817
2010's	62 (51.24)	24.3611
2020's	33 (27.27)	2.80

Authors

Authors	Studies
Balasubramanian, V; Bharath, S; Gaonkar, S; Jayaram, R; Jayashree, R; Kaur, P; Mahesh, BN; Nandi, V; Shandil, RK; Suresh, BL	1
Almeida, D; Bishai, WR; Grosset, J; Nuermberger, E; Tyagi, S	1
Aarnoutse, RE; Boeree, MJ; Kibiki, GS; Kisanga, ER; van den Boogaard, J	1
Ackerman, M; Cynamon, MH; Pucci, MJ; Shoen, CM; Thanassi, JA	1
Franzblau, SG; Garcia, GA; Gill, SK; Jin, Y; Kirchhoff, PD; Showalter, HD; Wan, B	1
Chen, L; Franzblau, SG; Liu, X; Lu, X; Wan, B; You, Q; Zhou, C	1
Baulard, AR; Crauste, C; Déprez, B; Flipo, M; Villemagne, B; Willand, N	1
Barry, CE; Dartois, V	1
Alfonso, S; Ballell, L; Barros Aguirre, D; Bates, RH; Biava, M; Cocozza, M; Consalvi, S; De Logu, A; Fernandez-Menendez, R; Poce, G; Venditti, G; Vistoli, G	1
Cheng, XW; Fan, YL; Feng, LS; Wu, JB; Zhang, FZ	1
Alemparte, C; Argyrou, A; Borthwick, JA; Burley, G; Cacho, M; de Dios-Anton, P; Guijarro, L; Monteiro, MC; Ortega, F; Pichel, JC; Suckling, CJ; Wall, I; Whitehurst, BC; Young, RJ	1
Aguirre, DB; Augustyns, K; Balabon, O; Ballell, L; Bates, RH; Cacho, M; Casanueva, R; Cunningham, F; Guijarro, L; Huss, S; Lopez-Roman, EM; Meiler, E; Pitta, E; Rogacki, MK; Santos-Villarejo, Á; Van der Veken, P	1
Bhagavathula, M; Bhatt, K; Deretic, VP; Ellner, JJ; Salgame, P; Timmins, GS; Verma, S	1
Blackman, A; Cáceres, T; Cachay, R; Gotuzzo, E; Maruri, F; Meza, E; Schwalb, A; Sterling, TR	1
Badal-Faesen, S; Bryant, K; Campbell, K; Chaisson, RE; Dawson, R; Dooley, KE; Dorman, SE; Fletcher, CV; Johnson, JL; Kurbatova, EV; Lalloo, U; Martinson, N; Mayanja, H; Mohapi, L; Nahid, P; Pettit, A; Pham, M; Phillips, PPJ; Podany, AT; Samaneka, W; Scott, N; Sizemore, E; Swindells, S; Vernon, A; Whitworth, WC	1
Akrami, S; Dokht Khosravi, A; Hashemzadeh, M	1
Carr, W; Converse, PJ; Dartois, V; Dooley, KE; Garcia, A; Kurbatova, E; Nuermberger, EL; Stout, JE; Tasneen, R; Vernon, AA; Zimmerman, MD	1
Arodola-Oladoyinbo, O; Chirehwa, M; Denti, P; Gengiah, TN; Kawuma, AN; Naidoo, A; Naidoo, K; Padayatchi, N; Perumal, R	1
Daneshfar, S; Hashemzadeh, M; Khosravi, AD	1
Bryant, K; Chaisson, RE; Dawson, R; Dooley, KE; Dorman, SE; Johnson, JL; Kurbatova, E; Lalloo, UG; Mohapi, L; Muzanyi, G; Nahid, P; Pettit, AC; Phillips, PPJ; Podany, AT; Samaneka, W; Sanne, I; Savic, RM; Scott, N; Sizemore, E; Swindells, S; Vernon, A; Waja, Z	1
Brankin, AE; Fowler, PW	1
He, Y; Li, X	1
Alghamdi, WA; Alsultan, A; Peloquin, C	1
Berg, A; Deshpande, D; Gumbo, T; Hanna, D; Hermann, D; Pasipanodya, JG; Romero, K; Srivastava, S	1
Dartois, V; Mittereder, LR; Namasivayam, S; Oland, S; Sher, A; Wang, H; Zimmerman, M	1
Bulychev, VV; Bulycheva, EV; Pashkova, NA	1
Chen, X; Feng, Z; Ge, S; Li, R; Li, Y; Miao, Y; Peng, Y; Song, L; Sun, F; Wang, X; Zhang, W; Zhang, Y	1
Brehm, TT; Friesen, I; Heyckendorf, J; Kalsdorf, B; Kandulla, J; Köhler, N; Kuhns, M; Lange, C; Martensen, J; Schmiedel, S; Terhalle, E	1
Borish, HJ; Budak, M; Chishti, HB; Cicchese, JM; Dartois, V; Fillmore, D; Flynn, JL; Frye, LJ; Kirschner, DE; Kracinovsky, K; Lin, PL; Linderman, JJ; Maiello, P; Sakal, J; Scanga, CA; Tomko, J; White, AG	1
Chopra, KK; Dwivedi, KK; Hanif, M; Khanna, A; Sidiq, Z; Vashishat, BK	1
Berge, I; Bogdanova, I; Freimane, L; Norvaiša, I; Ozere, I; Ranka, R; Sadovska, D; Vaivode, A; Vīksna, A	1
Aarnoutse, R; Boeree, M; Dombay, E; Eldirdiri, S; Gillespie, SH; Heinrich, N; Hoelscher, M; Kibiki, GS; Mtafya, B; Musisi, E; Ntinginya, NE; Sabiiti, W; Wyness, A	1
Aalhoul, F; Cotton, F; Fage, D	1
Bendet, P; Berg, A; Cirrincione, K; Deshpande, D; Gumbo, T; Hanna, D; Hermann, D; Magombedze, G; Martin, K; Romero, K; Srivastava, S; van Zyl, J	1
Furin, J; McKenna, L	1
de Jong, BC; Decroo, T; Lynen, L; Piubello, A; Van Deun, A	1
Caminero, JA; Caylà, JA; García-García, JM; García-Pérez, FJ; Palacios, JJ; Ruiz-Manzano, J	1
Draper, HR; Garcia-Prats, AJ; Hesseling, AC; Schaaf, HS; van der Laan, LE; Winckler, JL	1
Almoslem, M; Brown, D; Drusano, GL; Kim, S; Louie, A; Neely, M; Peloquin, CA; Rogers, S; Schmidt, S; Yamada, W	1
Alameer, R; Almaghrabi, RS; Almohaizeie, A; Alrajhi, AA; Alshehri, N; Nizami, I; Omrani, AS	1
Bishai, W; Dawson, R; De Jager, V; Diacon, A; Donahue, K; Fletcher, CV; Hafner, R; Hogg, E; Miyahara, S; Sun, X; Swindells, S; Urbanowski, M	1
Mizrahi, V; Rubin, EJ	1
Draper, HR; Fourie, B; Garcia-Prats, AJ; Hesseling, AC; Nielsen, J; Radtke, KK; Savic, RM; Schaaf, HS; Solans, BP; Thee, S; van der Laan, LE; Wiesner, L; Winckler, JL	1
de Jong, BC; Decroo, T; Gils, T; Lynen, L; Van Deun, A	1
Bao, L; Luo, T; Mi, Y; Peng, X; Sun, C; Wang, C; Yang, G; Yuan, J; Zhang, C	1
Essack, S; McIlleron, H; Naidoo, A; Naidoo, K; Padayatchi, N	1
Caylá, JA; García-Goez, JF; Miro, JM; Munera, GA; Pacheco, R; Rojas, V	1
Chaudhry, M; Chirehwa, M; Denti, P; McIlleron, H; Naidoo, A; Naidoo, K; Ngcapu, S; Padayatchi, N; Pepper, MS; Ramsuran, V; Singh, R; Yende-Zuma, N	1
Berg, A; Hanna, D; Hermann, D; Jamei, M; Patel, N; Polak, S; Romero, K	1
Bax, HI; de Knegt, GJ; de Steenwinkel, JEM; Mourik, BC; Simonsson, USH; Svensson, RJ; Verbon, A	1
Aktoğu Özkan, S; Biçmen, C; Çavuşoğlu, C; Eraç, B; Ermertcan, Ş; Hoşgör Limoncu, M; Yılmaz, FF	1
Brown, DL; Derendorf, H; Drusano, GL; Heinrichs, MT; Louie, A; Maynard, MS; Peloquin, CA; Rand, KH; Sy, SKB	1
Cirrincione, KN; Deshpande, D; Gumbo, T; Koeuth, T; Lee, PS; Martin, KR; Nuermberger, E; Srivastava, S	1
Chigutsa, E; Deshpande, D; Gumbo, T; Magombedze, G; McIlleron, H; Pasipanodya, JG; Srivastava, S; Visser, ME	1
Deshpande, D; Gumbo, T; Magombedze, G; Srivastava, S	1
Akkerman, OW; Alffenaar, JC; Johnson, JL; Kioumis, IP; Manika, K; Peloquin, C; Sturkenboom, MGG; Touw, DJ; van den Elsen, SHJ; van der Werf, TS	1
Akkerman, OW; Alffenaar, JC; Bolhuis, MS; de Lange, WCM; Dekkers, BGJ; Ter Beek, L; van der Werf, TS	1
Schaberg, T	1
Ahmad, Z; Grosset, JH; Minkowski, A; Nuermberger, EL; Peloquin, CA; Tyagi, S	1
Heilig, CM; Hey, SP; Weijer, C	1
Bian, A; Blackman, A; Eden, S; Maruri, F; Mitchel, E; Shintani, AK; Sterling, TR; van der Heijden, YF; Warkentin, JV	1
Chang, KC; Dheda, K	1
Aubry, A; Brossier, F; Chauffour, A; Fillion, A; Jarlier, V; Veziris, N	1
Jeong, BH; Koh, WJ; Kwon, YS	1
Bagcchi, S	1
Adrián Cataldi, A; Di Giulio, ÁB; Imperiale, BR; Morcillo, NS	1
Aarnoutse, RE; Alffenaar, JW; Boeree, MJ; Broeders, J; Burger, DM; Donders, AR; Later-Nijland, HM; Magis-Escurra, C; van Altena, R; van Crevel, R; van der Werf, TS	1
Amoabeng, O; Mdluli, KE; Minkowski, A; Nuermberger, EL; Tasneen, R; Upton, AM; Williams, K	1
Mayer, C; Takiff, H	1
Ai, J; Jin, J; Liu, Q; Ruan, Q; Shao, L; Sun, F; Yu, S; Zhang, B; Zhang, W	1
Bou-Chacra, N; Clas, SD; Gao, Y; Löbenberg, R; Roa, W; Sarfraz, M; Shi, W	1
Hussain, T; Moin, A; Nagshubha, B; Raizaday, A	1
Corelli, F; Frosini, M; Saponara, S; Sgaragli, G	1
Aubry, A; Bernard, C; Brossier, F; Chauffour, A; Robert, J; Veziris, N	1
Deshpande, D; Gumbo, T; Nuermberger, E; Pasipanodya, JG; Srivastava, S; Swaminathan, S	2
Goyal, S; Grover, A; Grover, S; Jamal, S; Kaur, J; Pandey, B; Singh, A; Tyagi, C	1
Bonora, S; Calcagno, A; Di Perri, G; Lucchini, A; Mondo, A; Trentini, L	1
Almeida, D; Grosset, JH; Nuermberger, EL; Rosenthal, IM; Zhang, M	1
Chen, YC; Ho, CC; Hu, FC; Luh, KT; Yang, PC; Yu, CJ	1
Andries, K; Guillemont, J; Jarlier, V; Koul, A; Lounis, N; Veziris, N	1
Gumbo, T	1
Daley, CL	1
Arnaud, P; Berdot, S; Bouvet, E; Diamantis, S; Dombret, MC; Papy, E; Rioux, C; Ruimy, R	1
Andries, K; Gevers, T; Lounis, N	1
Brown, DL; Drusano, GL; Eichas, A; Kulawy, R; Louie, A; Sgambati, N	1
Aubry, A; Chauffour, A; Farinotti, R; Fernandez, C; Jarlier, V; Lott, MC; Poissy, J; Veziris, N	1
Burman, W; Duran, P; Engle, M; Goldberg, S; Johnson, JL; Mugerwa, RD; Muzanye, G; Padayatchi, N; Prihoda, TJ; Sturm, AW; Weiner, M	1
Hutson, S	1
DeGroote, MA; Gilliland, JC; Kendall, LV; Lenaerts, AJ; Magden, ER; Weiner, CM	1
Cox, H; Ford, N; Goemaere, E; Keshavjee, S; McDermid, C; Mitnick, C; von Schoen-Angerer, T	1
Alffenaar, JW; Brouwers, JR; Koster, RA; Uges, DR; Vu, DH	1
Cremades, R; Galiana, A; García-Pachón, E; López, P; Rodríguez, JC; Royo, G; Ruiz-García, M	1
Ginsberg, A	1
Aryee, A; Bhagani, S; Breen, R; Cropley, I; Gadhok, R; Hopkins, S; Lipman, M; Murphy, M; Roberts, CH; Smith, C	1
Bishai, WR; Davis, SL; Harper, J; Jain, SK; Kramnik, I; Nuermberger, EL; Pomper, MG; Skerry, C; Tasneen, R; Weir, M	1
Roehr, B	1
Burki, T	1
Kmietowicz, Z	1
Bauer, TT; Bettermann, G; Blum, TG; Kollmeier, J; Mauch, H; Rüssmann, H; Schönfeld, N; Weiss, T	1
Geetharani, A; Hemanth Kumar, AK; Nandhakumar, B; Nandini, R; Ramachandran, G; Srinivasan, R; Sugirda, P; Tharani, CB	1
López, M; Rodríguez, JC; Royo, G; Ruiz, M	1
Gillespie, S; Gosling, R	1
Deziel, MR; Drusano, GL; Gumbo, T; Louie, A; Parsons, LM; Salfinger, M	1
Bishai, WR; Ginsburg, AS; Grosset, JH; Hamzeh, FM; Lee, J; Woolwine, SC	1
Bishai, WR; Calamita, H; Ginsburg, AS; Grosset, JH; Scott, CP; Sun, R	1
Bishai, WR; Grosset, JH; Nuermberger, E; Rosenthal, I; Tyagi, S; Williams, KN	1
Chauffour, A; Jarlier, V; Lounis, N; Truffot-Pernot, C; Veziris, N	1
Bloom, S	1
Andries, K; Chauffour, A; Jarlier, V; Lounis, N; Truffot-Pernot, C; Veziris, N	1
Bishai, WR; Chaisson, RE; Grosset, JH; Nuermberger, EL; Peloquin, CA; Rosenthal, IM; Tyagi, S; Vernon, AA; Williams, KN; Zhang, M	1
Ahmad, Z; Khuller, GK; Pandey, R; Sharma, S	1
Bagchi, S	1
Drlica, K; Kreiswirth, B; Zhao, X	1
Bonnafous, P; Grosset, J; Ji, B; Lounis, N; Maslo, C; Truffot-Pernot, C	1
Bentoucha, A; Grosset, J; Ji, B; Lounis, N; O'Brien, RJ; Roscigno, G; Truffot-Pernot, C; Vernon, A	1
Alvirez-Freites, EJ; Carter, JL; Cynamon, MH	1
Bishai, W; Chaisson, R; Grosset, J; Nuermberger, E; Tyagi, S; Yoshimatsu, T	1

Reviews

16 review(s) available for moxifloxacin and Koch's Disease

Article	Year
New drugs against tuberculosis: problems, progress, and evaluation of agents in clinical development. Antimicrobial agents and chemotherapy, 2009, Volume: 53, Issue:3 Topics: Animals; Antitubercular Agents; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Design; Drug Evaluation, Preclinical; Drug Resistance, Bacterial; Fluoroquinolones; Humans; Mycobacterium tuberculosis; Rifamycins; Tuberculosis	2009
Tuberculosis: the drug development pipeline at a glance. European journal of medicinal chemistry, 2012, Volume: 51 Topics: Animals; Antitubercular Agents; Clinical Trials as Topic; Drug Discovery; Humans; Tuberculosis	2012
A medicinal chemists' guide to the unique difficulties of lead optimization for tuberculosis. Bioorganic & medicinal chemistry letters, 2013, Sep-01, Volume: 23, Issue:17 Topics: Animals; Antitubercular Agents; Drug Discovery; Humans; Lung; Mycobacterium tuberculosis; Tuberculosis	2013
Fluoroquinolone derivatives and their anti-tubercular activities. European journal of medicinal chemistry, 2018, Feb-25, Volume: 146 Topics: Animals; Antitubercular Agents; Dose-Response Relationship, Drug; Fluoroquinolones; Humans; Molecular Structure; Mycobacterium tuberculosis; Structure-Activity Relationship; Tuberculosis	2018
The treatment effect of Levofloxacin, Moxifloxacin, and Gatifloxacin contained in the conventional therapy regimen for pulmonary tuberculosis: Systematic review and network meta-analysis. Medicine, 2022, Sep-23, Volume: 101, Issue:38 Topics: Antitubercular Agents; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Moxifloxacin; Network Meta-Analysis; Tuberculosis; Tuberculosis, Pulmonary	2022
[Treatment of tuberculosis: what is new?] Innere Medizin (Heidelberg, Germany), 2023, Volume: 64, Issue:7 Topics: Antitubercular Agents; Humans; Isoniazid; Moxifloxacin; Pyrazinamide; Tuberculosis; Tuberculosis, Multidrug-Resistant	2023
Pretomanid for tuberculosis: a systematic review. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 2022, Volume: 28, Issue:1 Topics: Antitubercular Agents; Humans; Linezolid; Moxifloxacin; Nitroimidazoles; Pyrazinamide; Randomized Controlled Trials as Topic; Rifampin; Tuberculosis; Tuberculosis, Multidrug-Resistant	2022
A Review of Moxifloxacin for the Treatment of Drug-Susceptible Tuberculosis. Journal of clinical pharmacology, 2017, Volume: 57, Issue:11 Topics: Animals; Antitubercular Agents; Drug Interactions; Fluoroquinolones; Humans; Moxifloxacin; Rifampin; Tuberculosis	2017
[Tuberculosis: new treatment options and updated recommendations]. Deutsche medizinische Wochenschrift (1946), 2013, Volume: 138, Issue:14 Topics: Antitubercular Agents; Aza Compounds; Cross-Sectional Studies; Diagnosis, Differential; Diarylquinolines; Fluoroquinolones; Germany; Humans; Moxifloxacin; Nitroimidazoles; Oxazoles; Prognosis; Quinolines; Rifampin; Tuberculosis; Tuberculosis, Multidrug-Resistant	2013
Tuberculosis: clinical trials and new drug regimens. Current opinion in pulmonary medicine, 2014, Volume: 20, Issue:3 Topics: Acetamides; Adamantane; Antitubercular Agents; Clinical Trials as Topic; Diarylquinolines; Drug Administration Schedule; Drug Design; Ethylenediamines; Female; Fluoroquinolones; Humans; Levofloxacin; Linezolid; Male; Moxifloxacin; Nitroimidazoles; Oxazoles; Oxazolidinones; Spiro Compounds; Thiazines; Tuberculosis; Tuberculosis, Multidrug-Resistant	2014
The Molecular Genetics of Fluoroquinolone Resistance in Mycobacterium tuberculosis. Microbiology spectrum, 2014, Volume: 2, Issue:4 Topics: Antitubercular Agents; DNA Gyrase; Drug Resistance, Bacterial; Drug Therapy, Combination; Fluoroquinolones; Humans; Moxifloxacin; Mutant Proteins; Mutation, Missense; Mycobacterium tuberculosis; Tuberculosis	2014
Moxifloxacin and gatifloxacin for initial therapy of tuberculosis: a meta-analysis of randomized clinical trials. Emerging microbes & infections, 2016, Feb-24, Volume: 5 Topics: Adult; Antitubercular Agents; Drug Therapy, Combination; Female; Fluoroquinolones; Gatifloxacin; Humans; Male; Moxifloxacin; Randomized Controlled Trials as Topic; Treatment Outcome; Tuberculosis	2016
Human Tuberculosis. III. Current and Prospective Approaches in Anti-Tubercular Therapy. Current medicinal chemistry, 2016, Volume: 23, Issue:21 Topics: Antitubercular Agents; Bacterial Proteins; Clinical Trials as Topic; Fluoroquinolones; Gatifloxacin; Humans; Moxifloxacin; Mycobacterium tuberculosis; Prospective Studies; Tuberculosis; Tuberculosis, Multidrug-Resistant	2016
[R207910 (TMC207): a new antibiotic for the treatment of tuberculosis]. Medecine et maladies infectieuses, 2010, Volume: 40, Issue:7 Topics: Animals; Anti-Infective Agents; Antitubercular Agents; Aza Compounds; Diarylquinolines; Disease Models, Animal; Drug Therapy, Combination; Enzyme Inhibitors; Ethionamide; Fluoroquinolones; Humans; Mice; Moxifloxacin; Mycobacterium tuberculosis; Placebos; Quinolines; Tuberculosis	2010
Update in tuberculosis 2009. American journal of respiratory and critical care medicine, 2010, Mar-15, Volume: 181, Issue:6 Topics: Acetamides; Animals; Antitubercular Agents; Aza Compounds; Diarylquinolines; Fluoroquinolones; Humans; Linezolid; Mice; Moxifloxacin; Oxazolidinones; Quinolines; Rifampin; Tuberculosis; Tuberculosis Vaccines; Vitamin D; Vitamins	2010
Moxifloxacin. Tuberculosis (Edinburgh, Scotland), 2008, Volume: 88, Issue:2 Topics: Animals; Antitubercular Agents; Aza Compounds; Fluoroquinolones; Humans; Moxifloxacin; Quinolines; Treatment Outcome; Tuberculosis	2008

Trials

4 trial(s) available for moxifloxacin and Koch's Disease

Article	Year
Efavirenz Pharmacokinetics and Human Immunodeficiency Virus Type 1 (HIV-1) Viral Suppression Among Patients Receiving Tuberculosis Treatment Containing Daily High-Dose Rifapentine. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2022, 09-10, Volume: 75, Issue:4 Topics: Alkynes; Anti-HIV Agents; Antitubercular Agents; Benzoxazines; Cyclopropanes; HIV Infections; HIV-1; Humans; Moxifloxacin; Rifampin; Tuberculosis	2022
Rifapentine With and Without Moxifloxacin for Pulmonary Tuberculosis in People With Human Immunodeficiency Virus (S31/A5349). Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2023, 02-08, Volume: 76, Issue:3 Topics: Antitubercular Agents; Drug Therapy, Combination; HIV; HIV Infections; Humans; Isoniazid; Moxifloxacin; Rifampin; Tuberculosis; Tuberculosis, Pulmonary	2023
Optimizing (O) rifapentine-based (RI) regimen and shortening (EN) the treatment of drug-susceptible tuberculosis (T) (ORIENT) using an adaptive seamless design: study protocol of a multicenter randomized controlled trial. BMC infectious diseases, 2023, May-08, Volume: 23, Issue:1 Topics: Clinical Trials, Phase II as Topic; Humans; Isoniazid; Moxifloxacin; Multicenter Studies as Topic; Pyrazinamide; Randomized Controlled Trials as Topic; Rifampin; Tuberculosis	2023
Assessing whether isoniazid is essential during the first 14 days of tuberculosis therapy: a phase 2a, open-label, randomised controlled trial. The Lancet. Microbe, 2020, Volume: 1, Issue:2 Topics: Adult; Antitubercular Agents; Drug Therapy, Combination; Ethambutol; Humans; Isoniazid; Moxifloxacin; Pyrazinamide; Rifampin; Tuberculosis	2020

Other Studies

101 other study(ies) available for moxifloxacin and Koch's Disease

Article	Year
Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy. Antimicrobial agents and chemotherapy, 2007, Volume: 51, Issue:2 Topics: Animals; Anti-Bacterial Agents; Antitubercular Agents; Aza Compounds; Ciprofloxacin; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Fluoroquinolones; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Ofloxacin; Predictive Value of Tests; Quinolines; Time Factors; Tuberculosis	2007
In vivo validation of the mutant selection window hypothesis with moxifloxacin in a murine model of tuberculosis. Antimicrobial agents and chemotherapy, 2007, Volume: 51, Issue:12 Topics: Animals; Anti-Infective Agents; Aza Compounds; Colony Count, Microbial; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Resistance, Bacterial; Fluoroquinolones; Lung; Mice; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Mycobacterium tuberculosis; Quinolines; Tuberculosis	2007
In vitro antituberculosis activities of ACH-702, a novel isothiazoloquinolone, against quinolone-susceptible and quinolone-resistant isolates. Antimicrobial agents and chemotherapy, 2010, Volume: 54, Issue:8 Topics: Antitubercular Agents; DNA Gyrase; Drug Resistance, Bacterial; Humans; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Quinolones; Thiazoles; Topoisomerase II Inhibitors; Tuberculosis	2010
Synthesis and structure-activity relationships of novel substituted 8-amino, 8-thio, and 1,8-pyrazole congeners of antitubercular rifamycin S and rifampin. Bioorganic & medicinal chemistry letters, 2011, Oct-15, Volume: 21, Issue:20 Topics: Antitubercular Agents; Escherichia coli; Humans; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Pyrazoles; Rifampin; Rifamycins; Tuberculosis	2011
Synthesis and evaluation of anti-tubercular and antibacterial activities of new 4-(2,6-dichlorobenzyloxy)phenyl thiazole, oxazole and imidazole derivatives. Part 2. European journal of medicinal chemistry, 2012, Volume: 49 Topics: Anti-Bacterial Agents; Antitubercular Agents; Bacteria; Bacterial Infections; Humans; Imidazoles; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Oxazoles; Thiazoles; Tuberculosis	2012
In vivo potent BM635 analogue with improved drug-like properties. European journal of medicinal chemistry, 2018, Feb-10, Volume: 145 Topics: Animals; Antitubercular Agents; Cell Proliferation; Cell Survival; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Design; Hep G2 Cells; Humans; Mice; Mice, Inbred C57BL; Microbial Sensitivity Tests; Molecular Structure; Mycobacterium tuberculosis; Pyrroles; Structure-Activity Relationship; Tuberculosis	2018
Journal of medicinal chemistry, 2020, 03-12, Volume: 63, Issue:5 Topics: Alcohol Oxidoreductases; Animals; Antitubercular Agents; Bacterial Proteins; Enzyme Inhibitors; Humans; Male; Mice; Morpholines; Mycobacterium tuberculosis; Pyrimidines; Tuberculosis	2020
Optimization of Hydantoins as Potent Antimycobacterial Decaprenylphosphoryl-β-d-Ribose Oxidase (DprE1) Inhibitors. Journal of medicinal chemistry, 2020, 05-28, Volume: 63, Issue:10 Topics: Alcohol Oxidoreductases; Animals; Antitubercular Agents; Bacterial Proteins; Female; Hep G2 Cells; Humans; Hydantoins; Mice; Mice, Inbred C57BL; Mycobacterium tuberculosis; Nuclear Magnetic Resonance, Biomolecular; Tuberculosis	2020
Rapamycin modulates pulmonary pathology in a murine model of Mycobacterium tuberculosis infection. Disease models & mechanisms, 2021, 10-01, Volume: 14, Issue:10 Topics: Animals; B-Lymphocytes; Cell Aggregation; Disease Models, Animal; Female; Lung; Mice; Moxifloxacin; Mycobacterium tuberculosis; Necrosis; Neutrophil Infiltration; Polymethacrylic Acids; Sirolimus; Tuberculosis	2021
Fluoroquinolone susceptibility in first-line drug-susceptible M. tuberculosis isolates in Lima, Peru. BMC research notes, 2021, Nov-14, Volume: 14, Issue:1 Topics: Antitubercular Agents; Drug Resistance, Bacterial; Fluoroquinolones; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Peru; Pharmaceutical Preparations; Tuberculosis; Tuberculosis, Multidrug-Resistant	2021
Drug resistance profiles and related gene mutations in slow-growing non-tuberculous mycobacteria isolated in regional tuberculosis reference laboratories of Iran: a three year cross-sectional study. Pathogens and global health, 2023, Volume: 117, Issue:1 Topics: Anti-Bacterial Agents; Clarithromycin; Cross-Sectional Studies; Drug Resistance, Multiple, Bacterial; Humans; Iran; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Mycobacterium Infections, Nontuberculous; Nontuberculous Mycobacteria; Rifampin; Tuberculosis	2023
Novel Regimens of Bedaquiline-Pyrazinamide Combined with Moxifloxacin, Rifabutin, Delamanid and/or OPC-167832 in Murine Tuberculosis Models. Antimicrobial agents and chemotherapy, 2022, 04-19, Volume: 66, Issue:4 Topics: Animals; Antibiotics, Antitubercular; Antitubercular Agents; Diarylquinolines; Disease Models, Animal; Drug Administration Schedule; Drug Therapy, Combination; Isoniazid; Mice; Mice, Inbred BALB C; Moxifloxacin; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Pyrazinamide; Rifabutin; Tuberculosis	2022
Altered drug exposures of first-line TB drugs in a moxifloxacin-containing treatment regimen. The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2022, 08-01, Volume: 26, Issue:8 Topics: Antitubercular Agents; Drug Therapy, Combination; Humans; Isoniazid; Moxifloxacin; Pregnanes; Pyrazinamide; Rifampin; South Africa; Tuberculosis	2022
Drug susceptibility profiling and genetic determinants of drug resistance in Mycobacterium simiae isolates obtained from regional tuberculosis reference laboratories of Iran. PloS one, 2022, Volume: 17, Issue:8 Topics: Amikacin; Anti-Bacterial Agents; Clarithromycin; Drug Resistance; Humans; Iran; Laboratories; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium; Mycobacterium Infections, Nontuberculous; Mycobacterium tuberculosis; Nontuberculous Mycobacteria; Tuberculosis	2022
Predicting antibiotic resistance in complex protein targets using alchemical free energy methods. Journal of computational chemistry, 2022, 10-05, Volume: 43, Issue:26 Topics: DNA Gyrase; Drug Resistance, Microbial; Humans; Moxifloxacin; Mutation; Mycobacterium tuberculosis; Tuberculosis	2022
Determining in vitro and ex vivo protein binding of levofloxacin and moxifloxacin in patients with TB. The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2022, 12-01, Volume: 26, Issue:12 Topics: Humans; Levofloxacin; Moxifloxacin; Protein Binding; Tuberculosis	2022
Hollow-fibre system model of tuberculosis reproducibility and performance specifications for best practice in drug and combination therapy development. The Journal of antimicrobial chemotherapy, 2023, 04-03, Volume: 78, Issue:4 Topics: Antitubercular Agents; Drug Therapy, Combination; Humans; Models, Biological; Moxifloxacin; Mycobacterium tuberculosis; Reproducibility of Results; Tuberculosis	2023
The Dysbiosis Triggered by First-Line Tuberculosis Antibiotics Fails to Reduce Their Bioavailability. mBio, 2023, 04-25, Volume: 14, Issue:2 Topics: Animals; Antitubercular Agents; Biological Availability; Dysbiosis; Humans; Isoniazid; Mice; Moxifloxacin; Pyrazinamide; Rifampin; Tuberculosis	2023
[The problem of formation of new risks of medicinal resistance of patients with tuberculosis in condition of active use of antibiotics by population under COVID-19]. Problemy sotsial'noi gigieny, zdravookhraneniia i istorii meditsiny, 2023, Volume: 31, Issue:2 Topics: Anti-Infective Agents; Antitubercular Agents; Azithromycin; COVID-19; Drug Resistance, Bacterial; Fluoroquinolones; Humans; Levofloxacin; Moxifloxacin; Mycobacterium tuberculosis; Pandemics; Quinolones; Tuberculosis	2023
Optimizing tuberculosis treatment efficacy: Comparing the standard regimen with Moxifloxacin-containing regimens. PLoS computational biology, 2023, Volume: 19, Issue:6 Topics: Animals; Antitubercular Agents; Mice; Moxifloxacin; Tuberculosis; Tuberculosis, Multidrug-Resistant	2023
Correlating clinical breakpoint concentration of moxifloxacin with gyrA mutations using the GenoType MTBDRsl assay Version 2.0. The Indian journal of tuberculosis, 2023, Volume: 70, Issue:3 Topics: Antitubercular Agents; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Genotype; Humans; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Mycobacterium tuberculosis; Tuberculosis; Tuberculosis, Multidrug-Resistant	2023
Genotypic and phenotypic comparison of drug resistance profiles of clinical multidrug-resistant Mycobacterium tuberculosis isolates using whole genome sequencing in Latvia. BMC infectious diseases, 2023, Sep-28, Volume: 23, Issue:1 Topics: Amikacin; Antitubercular Agents; Capreomycin; Drug Resistance, Multiple, Bacterial; Ethambutol; Ethionamide; Humans; Isoniazid; Kanamycin; Latvia; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Rifampin; Tuberculosis; Tuberculosis, Multidrug-Resistant; Whole Genome Sequencing	2023
Effect of seven anti-tuberculosis treatment regimens on sputum microbiome: a retrospective analysis of the HIGHRIF study 2 and PanACEA MAMS-TB clinical trials. The Lancet. Microbe, 2023, Volume: 4, Issue:11 Topics: Antitubercular Agents; Clinical Trials as Topic; Drug Therapy, Combination; Humans; Microbiota; Moxifloxacin; Retrospective Studies; RNA, Ribosomal, 16S; Sputum; Tanzania; Tuberculosis; Tuberculosis, Pulmonary	2023
Protein binding investigation of first-line and second-line antituberculosis drugs. International journal of antimicrobial agents, 2023, Volume: 62, Issue:6 Topics: Antitubercular Agents; Ethambutol; Humans; Isoniazid; Levofloxacin; Linezolid; Moxifloxacin; Protein Binding; Pyrazinamide; Rifampin; Tuberculosis	2023
Duration of pretomanid/moxifloxacin/pyrazinamide therapy compared with standard therapy based on time-to-extinction mathematics. The Journal of antimicrobial chemotherapy, 2020, 02-01, Volume: 75, Issue:2 Topics: Antitubercular Agents; Drug Therapy, Combination; Humans; Mathematics; Moxifloxacin; Mycobacterium tuberculosis; Nitroimidazoles; Pyrazinamide; Tuberculosis	2020
Are pretomanid-containing regimens for tuberculosis a victory or a victory narrative? The Lancet. Respiratory medicine, 2019, Volume: 7, Issue:12 Topics: Diarylquinolines; Humans; Moxifloxacin; Nitroimidazoles; Pyrazinamide; Tuberculosis; Tuberculosis, Pulmonary	2019
Tuberculosis treatment: one-shot approach or cascade of regimens? The Lancet. Respiratory medicine, 2020, Volume: 8, Issue:2 Topics: Diarylquinolines; Humans; Moxifloxacin; Nitroimidazoles; Pyrazinamide; Tuberculosis; Tuberculosis, Pulmonary	2020
Update of SEPAR guideline «Diagnosis and Treatment of Drug-Resistant Tuberculosis». Archivos de bronconeumologia, 2020, Volume: 56, Issue:8 Topics: Antitubercular Agents; Humans; Linezolid; Moxifloxacin; Tuberculosis; Tuberculosis, Multidrug-Resistant	2020
Acceptability of levofloxacin, moxifloxacin and linezolid among children and adolescents treated for TB. The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2020, 12-01, Volume: 24, Issue:12 Topics: Adolescent; Anti-Bacterial Agents; Aza Compounds; Child; Fluoroquinolones; Humans; Levofloxacin; Linezolid; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Tuberculosis	2020
Dose Fractionation of Moxifloxacin for Treatment of Tuberculosis: Impact of Dosing Interval and Elimination Half-Life on Microbial Kill and Resistance Suppression. Antimicrobial agents and chemotherapy, 2021, 03-18, Volume: 65, Issue:4 Topics: Antitubercular Agents; Area Under Curve; Fluoroquinolones; Half-Life; Humans; Microbial Sensitivity Tests; Moxifloxacin; Tuberculosis	2021
Successful Use of Rifamycin-Sparing Regimens for the Treatment of Active Tuberculosis in Lung Transplant Recipients. Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation, 2021, Volume: 19, Issue:4 Topics: Ethambutol; Humans; Isoniazid; Lung; Lung Transplantation; Moxifloxacin; Pyrazinamide; Rifamycins; Transplant Recipients; Treatment Outcome; Tuberculosis	2021
Shortening the Short Course of Tuberculosis Treatment. The New England journal of medicine, 2021, 05-06, Volume: 384, Issue:18 Topics: Humans; Moxifloxacin; Rifampin; Tuberculosis	2021
Moxifloxacin Pharmacokinetics, Cardiac Safety, and Dosing for the Treatment of Rifampicin-Resistant Tuberculosis in Children. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2022, 04-28, Volume: 74, Issue:8 Topics: Adult; Child; Child, Preschool; Electrocardiography; Fluoroquinolones; HIV Infections; Humans; Moxifloxacin; Rifampin; Tuberculosis; Tuberculosis, Multidrug-Resistant	2022
Double mutation in DNA gyrase confers moxifloxacin resistance and decreased fitness of Mycobacterium smegmatis. The Journal of antimicrobial chemotherapy, 2017, 07-01, Volume: 72, Issue:7 Topics: DNA Gyrase; Drug Resistance, Bacterial; Fluoroquinolones; Genetic Fitness; Genomics; Humans; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Mycobacterium smegmatis; Mycobacterium tuberculosis; Ofloxacin; Sequence Analysis, DNA; Tuberculosis; Tuberculosis, Multidrug-Resistant	2017
Tuberculosis in recipients of solid-organ transplants during 1995-2015 in Cali, Colombia. The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2017, 11-01, Volume: 21, Issue:11 Topics: Adolescent; Adult; Antitubercular Agents; Colombia; Female; Fluoroquinolones; Graft Rejection; Humans; Male; Middle Aged; Moxifloxacin; Opportunistic Infections; Organ Transplantation; Retrospective Studies; Rifampin; Risk Factors; Sputum; Transplant Recipients; Treatment Outcome; Tuberculosis; Tuberculosis, Pulmonary; Young Adult	2017
Effect of genetic variation in UGT1A and ABCB1 on moxifloxacin pharmacokinetics in South African patients with tuberculosis. Pharmacogenomics, 2018, Volume: 19, Issue:1 Topics: Adult; Anti-Bacterial Agents; ATP Binding Cassette Transporter, Subfamily B; Female; Fluoroquinolones; Genotype; Glucuronosyltransferase; Humans; Male; Moxifloxacin; Polymorphism, Single Nucleotide; Prospective Studies; Tuberculosis	2018
Quantitative approach for cardiac risk assessment and interpretation in tuberculosis drug development. Journal of pharmacokinetics and pharmacodynamics, 2018, Volume: 45, Issue:3 Topics: Adult; Algorithms; Antitubercular Agents; Cardiotoxicity; Diarylquinolines; Drug Development; Electrocardiography; Female; Heart; Humans; Male; Moxifloxacin; Risk Assessment; Sensitivity and Specificity; Torsades de Pointes; Tuberculosis	2018
Improving treatment outcome assessment in a mouse tuberculosis model. Scientific reports, 2018, 04-09, Volume: 8, Issue:1 Topics: Administration, Oral; Animals; Antitubercular Agents; Disease Models, Animal; Drug Therapy, Combination; Ethambutol; Female; Genotype; Humans; Mice; Mice, Inbred BALB C; Models, Theoretical; Moxifloxacin; Mycobacterium tuberculosis; Pyrazinamide; Rifampin; Treatment Outcome; Tuberculosis	2018
In vitro effects of ciprofloxacin, levofloxacin and moxifloxacin on Mycobacterium tuberculosis isolates. Tuberkuloz ve toraks, 2018, Volume: 66, Issue:1 Topics: Antitubercular Agents; Ciprofloxacin; Fluoroquinolones; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Tuberculosis; Tuberculosis, Multidrug-Resistant; Turkey	2018
Dose optimization of moxifloxacin and linezolid against tuberculosis using mathematical modeling and simulation. International journal of antimicrobial agents, 2019, Volume: 53, Issue:3 Topics: Anti-Bacterial Agents; Drug Resistance, Bacterial; Humans; Linezolid; Microbial Viability; Models, Theoretical; Moxifloxacin; Mycobacterium tuberculosis; Treatment Outcome; Tuberculosis	2019
Multiparameter Responses to Tedizolid Monotherapy and Moxifloxacin Combination Therapy Models of Children With Intracellular Tuberculosis. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2018, 11-28, Volume: 67, Issue:suppl_3 Topics: Anti-Bacterial Agents; Child; Dose-Response Relationship, Drug; Humans; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Oxazolidinones; Tetrazoles; Tuberculosis	2018
Transformation Morphisms and Time-to-Extinction Analysis That Map Therapy Duration From Preclinical Models to Patients With Tuberculosis: Translating From Apples to Oranges. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2018, 11-28, Volume: 67, Issue:suppl_3 Topics: Antitubercular Agents; Clinical Trials as Topic; Drug Discovery; Drug Evaluation, Preclinical; Ethambutol; Humans; Isoniazid; Models, Biological; Moxifloxacin; Mycobacterium tuberculosis; Recurrence; Sputum; Tuberculosis	2018
Efficacy Versus Hepatotoxicity of High-dose Rifampin, Pyrazinamide, and Moxifloxacin to Shorten Tuberculosis Therapy Duration: There Is Still Fight in the Old Warriors Yet! Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2018, 11-28, Volume: 67, Issue:suppl_3 Topics: Antitubercular Agents; Chemical and Drug Induced Liver Injury; Dose-Response Relationship, Drug; Humans; Liver; Models, Biological; Moxifloxacin; Mycobacterium tuberculosis; Pyrazinamide; Rifampin; Time Factors; Tuberculosis	2018
Limited Sampling Strategies Using Linear Regression and the Bayesian Approach for Therapeutic Drug Monitoring of Moxifloxacin in Tuberculosis Patients. Antimicrobial agents and chemotherapy, 2019, Volume: 63, Issue:7 Topics: Adult; Antitubercular Agents; Area Under Curve; Bayes Theorem; Drug Monitoring; Drug Therapy, Combination; Female; Humans; Linear Models; Male; Middle Aged; Moxifloxacin; Reproducibility of Results; Rifampin; Tuberculosis	2019
Reduced moxifloxacin exposure in patients with tuberculosis and diabetes. The European respiratory journal, 2019, Volume: 54, Issue:3 Topics: Adult; Antitubercular Agents; Comorbidity; Diabetes Mellitus; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Moxifloxacin; Tuberculosis	2019
Contribution of moxifloxacin or levofloxacin in second-line regimens with or without continuation of pyrazinamide in murine tuberculosis. American journal of respiratory and critical care medicine, 2013, Jul-01, Volume: 188, Issue:1 Topics: Analysis of Variance; Animals; Anti-Bacterial Agents; Antitubercular Agents; Aza Compounds; Disease Models, Animal; Drug Administration Schedule; Drug Therapy, Combination; Female; Fluoroquinolones; Levofloxacin; Mice; Mice, Inbred BALB C; Moxifloxacin; Ofloxacin; Pyrazinamide; Quinolines; Treatment Outcome; Tuberculosis	2013
Accumulating Evidence and Research Organization (AERO) model: a new tool for representing, analyzing, and planning a translational research program. Trials, 2013, May-30, Volume: 14 Topics: Animals; Antitubercular Agents; Aza Compounds; Computer Graphics; Evidence-Based Medicine; Fluoroquinolones; Humans; Models, Organizational; Moxifloxacin; Organizational Objectives; Photic Stimulation; Quinolines; Time Factors; Translational Research, Biomedical; Treatment Outcome; Tuberculosis; Visual Perception; Workflow	2013
Fluoroquinolone susceptibility in Mycobacterium tuberculosis after pre-diagnosis exposure to older- versus newer-generation fluoroquinolones. International journal of antimicrobial agents, 2013, Volume: 42, Issue:3 Topics: Adult; Aged; Anti-Bacterial Agents; Aza Compounds; Case-Control Studies; Ciprofloxacin; DNA Gyrase; Drug Resistance, Bacterial; Female; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Male; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Mycobacterium tuberculosis; Ofloxacin; Quinolines; Tuberculosis	2013
Rationalizing use of fluoroquinolones and pyrazinamide in the battle against multidrug-resistant tuberculosis. American journal of respiratory and critical care medicine, 2013, Jul-01, Volume: 188, Issue:1 Topics: Animals; Anti-Bacterial Agents; Antitubercular Agents; Aza Compounds; Female; Fluoroquinolones; Moxifloxacin; Ofloxacin; Pyrazinamide; Quinolines; Tuberculosis	2013
Impact of fluoroquinolone resistance on bactericidal and sterilizing activity of a moxifloxacin-containing regimen in murine tuberculosis. Antimicrobial agents and chemotherapy, 2013, Volume: 57, Issue:9 Topics: Amikacin; Animals; Antitubercular Agents; Aza Compounds; DNA Gyrase; Drug Administration Schedule; Drug Resistance, Bacterial; Ethionamide; Female; Fluoroquinolones; Mice; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Mycobacterium tuberculosis; Ofloxacin; Quinolines; Recurrence; Rodent Diseases; Survival Analysis; Tuberculosis	2013
Novel drug combination for tuberculosis to be tested across 50 sites. BMJ (Clinical research ed.), 2014, May-27, Volume: 348 Topics: Antitubercular Agents; Aza Compounds; Clinical Trials, Phase II as Topic; Drug Therapy, Combination; Fluoroquinolones; Humans; Moxifloxacin; Nitroimidazoles; Pyrazinamide; Quinolines; Tuberculosis	2014
Evaluation of Mycobacterium tuberculosis cross-resistance to isoniazid, rifampicin and levofloxacin with their respective structural analogs. The Journal of antibiotics, 2014, Volume: 67, Issue:11 Topics: Antitubercular Agents; Base Sequence; Colorimetry; Drug Resistance, Bacterial; Ethionamide; Fluoroquinolones; Humans; Isoniazid; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Mycobacterium tuberculosis; Open Reading Frames; Rifabutin; Rifampin; Sequence Analysis, DNA; Tuberculosis	2014
Population pharmacokinetics and limited sampling strategy for first-line tuberculosis drugs and moxifloxacin. International journal of antimicrobial agents, 2014, Volume: 44, Issue:3 Topics: Adolescent; Adult; Aged; Antitubercular Agents; Area Under Curve; Female; Fluoroquinolones; Humans; Male; Middle Aged; Moxifloxacin; Netherlands; Tuberculosis; Young Adult	2014
Contribution of the nitroimidazoles PA-824 and TBA-354 to the activity of novel regimens in murine models of tuberculosis. Antimicrobial agents and chemotherapy, 2015, Volume: 59, Issue:1 Topics: Animals; Antitubercular Agents; Clofazimine; Diarylquinolines; Disease Models, Animal; Drug Therapy, Combination; Female; Fluoroquinolones; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Nitroimidazoles; Oxazines; Oxazoles; Pyrazinamide; Random Allocation; Tuberculosis	2015
Immune response to antituberculosis drug-loaded gelatin and polyisobutyl-cyanoacrylate nanoparticles in macrophages. Therapeutic delivery, 2016, Volume: 7, Issue:4 Topics: Animals; Antitubercular Agents; Cell Line; Cell Survival; Chromatography, High Pressure Liquid; Cyanoacrylates; Cytokines; Drug Carriers; Drug Liberation; Dynamic Light Scattering; Enbucrilate; Enzyme-Linked Immunosorbent Assay; Fluoroquinolones; Gelatin; Macrophages; Mice; Microscopy, Electron, Transmission; Moxifloxacin; Nanoparticles; Rifampin; Spectrophotometry, Ultraviolet; Tuberculosis	2016
Development and Optimization of Dual Drugs (Isoniazid and Moxiflox-acin) Loaded Functional PLGA Nanoparticles for the Synergistic Treatment of Tuberculosis. Current drug delivery, 2016, Volume: 13, Issue:7 Topics: Anti-Bacterial Agents; Drug Carriers; Drug Liberation; Drug Resistance, Bacterial; Drug Resistance, Multiple; Drug Synergism; Drug Therapy, Combination; Fluoroquinolones; Isoniazid; Lactic Acid; Magnetic Resonance Spectroscopy; Microscopy, Electron, Scanning; Moxifloxacin; Nanoparticles; Particle Size; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Spectroscopy, Fourier Transform Infrared; Tuberculosis	2016
In vivo Mycobacterium tuberculosis fluoroquinolone resistance emergence: a complex phenomenon poorly detected by current diagnostic tests. The Journal of antimicrobial chemotherapy, 2016, Volume: 71, Issue:12 Topics: Animals; Antitubercular Agents; Disease Models, Animal; Drug Resistance, Bacterial; Female; Fluoroquinolones; Genotyping Techniques; Mice; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Ofloxacin; Selection, Genetic; Tuberculosis	2016
Concentration-Dependent Synergy and Antagonism of Linezolid and Moxifloxacin in the Treatment of Childhood Tuberculosis: The Dynamic Duo. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2016, Nov-01, Volume: 63, Issue:suppl 3 Topics: Age Factors; Antitubercular Agents; Bacterial Load; Cell Line; Child; Computer Simulation; Drug Antagonism; Drug Synergism; Drug Therapy, Combination; Fluoroquinolones; Humans; Linezolid; Microbial Sensitivity Tests; Models, Theoretical; Moxifloxacin; Mycobacterium tuberculosis; Tuberculosis	2016
A Faropenem, Linezolid, and Moxifloxacin Regimen for Both Drug-Susceptible and Multidrug-Resistant Tuberculosis in Children: FLAME Path on the Milky Way. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2016, Nov-01, Volume: 63, Issue:suppl 3 Topics: Antitubercular Agents; Bacterial Load; beta-Lactams; Child; Computer Simulation; Dose-Response Relationship, Drug; Drug Therapy, Combination; Fluoroquinolones; Humans; Linezolid; Microbial Sensitivity Tests; Models, Theoretical; Moxifloxacin; Mycobacterium tuberculosis; Tuberculosis; Tuberculosis, Multidrug-Resistant	2016
Dynamics of fluoroquinolones induced resistance in DNA gyrase of Mycobacterium tuberculosis. Journal of biomolecular structure & dynamics, 2018, Volume: 36, Issue:2 Topics: DNA Gyrase; Drug Resistance, Bacterial; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Molecular Docking Simulation; Molecular Structure; Moxifloxacin; Mutation; Mycobacterium tuberculosis; Structure-Activity Relationship; Topoisomerase II Inhibitors; Tuberculosis	2018
Moxifloxacin for the treatment of HIV-associated tuberculosis in patients with contraindications or intolerance to rifamycins. The Journal of infection, 2008, Volume: 57, Issue:1 Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Bacterial Agents; Aza Compounds; Contraindications; Drug Resistance, Bacterial; Fluoroquinolones; HIV Infections; Humans; Male; Middle Aged; Moxifloxacin; Mycobacterium tuberculosis; Quinolines; Rifamycins; Treatment Outcome; Tuberculosis	2008
Isoniazid or moxifloxacin in rifapentine-based regimens for experimental tuberculosis? American journal of respiratory and critical care medicine, 2008, Nov-01, Volume: 178, Issue:9 Topics: Animals; Antibiotics, Antitubercular; Antitubercular Agents; Aza Compounds; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluoroquinolones; Isoniazid; Lung; Mice; Mice, Inbred BALB C; Moxifloxacin; Pyrazinamide; Quinolines; Recurrence; Rifampin; Time Factors; Treatment Outcome; Tuberculosis	2008
Safety of fluoroquinolone use in patients with hepatotoxicity induced by anti-tuberculosis regimens. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2009, Jun-01, Volume: 48, Issue:11 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alanine Transaminase; Anti-Bacterial Agents; Antitubercular Agents; Aspartate Aminotransferases; Aza Compounds; Ethambutol; Female; Fluoroquinolones; Hepatic Insufficiency; Humans; Levofloxacin; Male; Middle Aged; Moxifloxacin; Ofloxacin; Quinolines; Streptomycin; Treatment Outcome; Tuberculosis; Young Adult	2009
New susceptibility breakpoints for first-line antituberculosis drugs based on antimicrobial pharmacokinetic/pharmacodynamic science and population pharmacokinetic variability. Antimicrobial agents and chemotherapy, 2010, Volume: 54, Issue:4 Topics: Antitubercular Agents; Aza Compounds; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Ethambutol; Fluoroquinolones; Humans; In Vitro Techniques; Isoniazid; Microbial Sensitivity Tests; Models, Biological; Monte Carlo Method; Moxifloxacin; Mycobacterium tuberculosis; Pyrazinamide; Quinolines; Rifampin; Tuberculosis; Tuberculosis, Multidrug-Resistant	2010
[Use of moxifloxacin in tuberculosis regimen in a French teaching hospital]. Medecine et maladies infectieuses, 2010, Volume: 40, Issue:10 Topics: Adult; Aged; Antitubercular Agents; Aza Compounds; Comorbidity; Drug Prescriptions; Drug Therapy, Combination; Drug Utilization; Female; Fluoroquinolones; France; HIV Infections; Hospitals, University; Humans; Male; Middle Aged; Moxifloxacin; Quinolines; Recurrence; Retrospective Studies; Tuberculosis; Young Adult	2010
Bactericidal potencies of new regimens are not predictive of their sterilizing potencies in a murine model of tuberculosis. Antimicrobial agents and chemotherapy, 2010, Volume: 54, Issue:11 Topics: Animals; Antibiotics, Antitubercular; Aza Compounds; Diarylquinolines; Disease Models, Animal; Female; Fluoroquinolones; Mice; Moxifloxacin; Mycobacterium tuberculosis; Pyrazinamide; Quinolines; Rifampin; Tuberculosis	2010
The combination of rifampin plus moxifloxacin is synergistic for suppression of resistance but antagonistic for cell kill of Mycobacterium tuberculosis as determined in a hollow-fiber infection model. mBio, 2010, Aug-10, Volume: 1, Issue:3 Topics: Antitubercular Agents; Aza Compounds; Drug Evaluation, Preclinical; Drug Resistance, Bacterial; Drug Synergism; Fluoroquinolones; Humans; Microbial Viability; Models, Biological; Moxifloxacin; Mycobacterium tuberculosis; Quinolines; Rifampin; Tuberculosis	2010
Should moxifloxacin be used for the treatment of extensively drug-resistant tuberculosis? An answer from a murine model. Antimicrobial agents and chemotherapy, 2010, Volume: 54, Issue:11 Topics: Animals; Antitubercular Agents; Aza Compounds; DNA Gyrase; Enoxacin; Fluoroquinolones; Gatifloxacin; Mice; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Mycobacterium tuberculosis; Ofloxacin; Quinolines; Tuberculosis; Tuberculosis, Multidrug-Resistant	2010
Evaluation of time to detection of Mycobacterium tuberculosis in broth culture as a determinant for end points in treatment trials. Journal of clinical microbiology, 2010, Volume: 48, Issue:12 Topics: Adult; Antitubercular Agents; Aza Compounds; Bacteriological Techniques; Clinical Trials as Topic; Drug Monitoring; Ethambutol; Female; Fluoroquinolones; Humans; Male; Middle Aged; Moxifloxacin; Mycobacterium tuberculosis; Quinolines; Time Factors; Tuberculosis	2010
Half-century-old TB drugs get a facelift in new cocktails. Nature medicine, 2010, Volume: 16, Issue:12 Topics: Antitubercular Agents; Aza Compounds; Clinical Trials as Topic; Drug Discovery; Drug Therapy, Combination; Fluoroquinolones; Humans; Moxifloxacin; Nitroimidazoles; Pyrazinamide; Quinolines; Tuberculosis	2010
Torticollis in mice intravenously infected with Mycobacterium tuberculosis. Journal of the American Association for Laboratory Animal Science : JAALAS, 2011, Volume: 50, Issue:2 Topics: Animals; Antitubercular Agents; Autopsy; Aza Compounds; Disease Models, Animal; Drug Therapy, Combination; Ear, Middle; Female; Fluoroquinolones; Injections, Intravenous; Isoniazid; Mice; Mice, Inbred BALB C; Moxifloxacin; Mycobacterium tuberculosis; Otitis Media; Pyrazinamide; Quinolines; Rifampin; Torticollis; Tuberculosis	2011
Rational use of moxifloxacin for tuberculosis treatment. The Lancet. Infectious diseases, 2011, Volume: 11, Issue:4 Topics: Antitubercular Agents; Aza Compounds; Clinical Trials as Topic; Fluoroquinolones; Humans; Moxifloxacin; Mycobacterium tuberculosis; Quinolines; Treatment Outcome; Tuberculosis	2011
Determination of moxifloxacin in dried blood spots using LC-MS/MS and the impact of the hematocrit and blood volume. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2011, May-01, Volume: 879, Issue:15-16 Topics: Antitubercular Agents; Aza Compounds; Blood Specimen Collection; Blood Volume; Chromatography, Liquid; Drug Monitoring; Drug Stability; Fluoroquinolones; Hematocrit; Humans; Linear Models; Moxifloxacin; Quinolines; Reproducibility of Results; Sensitivity and Specificity; Tandem Mass Spectrometry; Tuberculosis	2011
Comparison of the bactericidal activity of various fluoroquinolones against Mycobacterium tuberculosis in an in vitro experimental model. The Journal of antimicrobial chemotherapy, 2011, Volume: 66, Issue:10 Topics: Antitubercular Agents; Aza Compounds; Ciprofloxacin; Drug Resistance, Bacterial; Fluoroquinolones; Humans; Isoniazid; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Ofloxacin; Quinolines; Spain; Tuberculosis	2011
The TB Alliance: overcoming challenges to chart the future course of TB drug development. Future medicinal chemistry, 2011, Volume: 3, Issue:10 Topics: Antitubercular Agents; Aza Compounds; Clinical Trials as Topic; Diarylquinolines; Drug Evaluation, Preclinical; Fluoroquinolones; Humans; Models, Organizational; Moxifloxacin; Nitroimidazoles; Quinolines; Tuberculosis	2011
Hepatotoxicity in the treatment of tuberculosis using moxifloxacin-containing regimens. The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2011, Volume: 15, Issue:9 Topics: Antitubercular Agents; Aza Compounds; Chemical and Drug Induced Liver Injury; Cohort Studies; Drug Therapy, Combination; Fluoroquinolones; Humans; Logistic Models; Moxifloxacin; Multivariate Analysis; Quinolines; Retrospective Studies; Tuberculosis	2011
Mouse model of necrotic tuberculosis granulomas develops hypoxic lesions. The Journal of infectious diseases, 2012, Feb-15, Volume: 205, Issue:4 Topics: Animals; Antitubercular Agents; Aza Compounds; Disease Models, Animal; Fluoroquinolones; Gene Expression Profiling; Genes, Bacterial; Granuloma; Hypoxia; Immunohistochemistry; Male; Mice; Mice, Inbred C3H; Moxifloxacin; Mycobacterium tuberculosis; Nitroimidazoles; Positron-Emission Tomography; Pyrazinamide; Quinolines; Treatment Outcome; Tuberculosis	2012
Trial tests new combination of drugs to treat tuberculosis. BMJ (Clinical research ed.), 2012, Mar-20, Volume: 344 Topics: AIDS-Related Opportunistic Infections; Antitubercular Agents; Aza Compounds; Clinical Trials as Topic; Drug Administration Schedule; Drug Resistance, Bacterial; Drug Therapy, Combination; Fluoroquinolones; Humans; Moxifloxacin; Mycobacterium tuberculosis; Nitroimidazoles; Pyrazinamide; Quinolines; Research Support as Topic; Tuberculosis; United States	2012
PanACEA: a new approach to tuberculosis research. The Lancet. Infectious diseases, 2012, Volume: 12, Issue:3 Topics: Africa South of the Sahara; Antitubercular Agents; Aza Compounds; Biomedical Research; Cooperative Behavior; Europe; Fluoroquinolones; Humans; Moxifloxacin; Quinolines; Tuberculosis	2012
New drug combination for TB is tested in unique trial. BMJ (Clinical research ed.), 2012, Jul-25, Volume: 345 Topics: Antitubercular Agents; Aza Compounds; Clinical Trials as Topic; Drug Combinations; Fluoroquinolones; Humans; Moxifloxacin; Nitroimidazoles; Pyrazinamide; Quinolines; Tuberculosis	2012
In vitro susceptibility of Mycobacterium bovis against moxifloxacin. The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2012, Volume: 16, Issue:11 Topics: Antitubercular Agents; Aza Compounds; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium bovis; Quinolines; Retrospective Studies; Tuberculosis	2012
Effect of rifampicin & isoniazid on the steady state pharmacokinetics of moxifloxacin. The Indian journal of medical research, 2012, Volume: 136, Issue:6 Topics: Adult; Area Under Curve; Aza Compounds; Chromatography, High Pressure Liquid; Fluoroquinolones; Humans; Isoniazid; Microbial Sensitivity Tests; Moxifloxacin; Quinolines; Rifampin; Tuberculosis	2012
In vitro activity of moxifloxacin, levofloxacin, gatifloxacin and linezolid against Mycobacterium tuberculosis. International journal of antimicrobial agents, 2002, Volume: 20, Issue:6 Topics: Acetamides; Adult; Aged; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Drug Resistance, Multiple, Bacterial; Female; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Linezolid; Male; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Ofloxacin; Oxazolidinones; Quinolines; Tuberculosis	2002
Moxifloxacin treatment of tuberculosis. Antimicrobial agents and chemotherapy, 2004, Volume: 48, Issue:9 Topics: Anti-Bacterial Agents; Antitubercular Agents; Aza Compounds; Colony Count, Microbial; Fluoroquinolones; Humans; Isoniazid; Moxifloxacin; Quinolines; Serum Bactericidal Test; Sputum; Tuberculosis	2004
Selection of a moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical modeling. The Journal of infectious diseases, 2004, Nov-01, Volume: 190, Issue:9 Topics: Antitubercular Agents; Aza Compounds; Colony Count, Microbial; Drug Resistance, Bacterial; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Models, Biological; Monte Carlo Method; Moxifloxacin; Mycobacterium tuberculosis; Quinolines; Tuberculosis	2004
Modeling in vivo pharmacokinetics and pharmacodynamics of moxifloxacin therapy for Mycobacterium tuberculosis infection by using a novel cartridge system. Antimicrobial agents and chemotherapy, 2005, Volume: 49, Issue:2 Topics: Algorithms; Anti-Bacterial Agents; Aza Compounds; Colony Count, Microbial; Computer Simulation; Fluoroquinolones; Half-Life; Infusion Pumps; Models, Biological; Moxifloxacin; Quinolines; Tuberculosis	2005
Emergence of fluoroquinolone resistance in Mycobacterium tuberculosis during continuously dosed moxifloxacin monotherapy in a mouse model. Antimicrobial agents and chemotherapy, 2005, Volume: 49, Issue:9 Topics: Animals; Anti-Bacterial Agents; Aza Compounds; Body Weight; Diet; DNA Gyrase; DNA Primers; Drug Resistance, Bacterial; Eating; Female; Fluoroquinolones; Mice; Mice, Inbred BALB C; Moxifloxacin; Mycobacterium tuberculosis; Quinolines; Reverse Transcriptase Polymerase Chain Reaction; Tuberculosis	2005
Rifapentine, moxifloxacin, or DNA vaccine improves treatment of latent tuberculosis in a mouse model. American journal of respiratory and critical care medicine, 2005, Dec-01, Volume: 172, Issue:11 Topics: Animals; Antibiotics, Antitubercular; Aza Compounds; Colony Count, Microbial; Disease Models, Animal; Drug Therapy, Combination; Female; Fluoroquinolones; Follow-Up Studies; Mice; Mice, Inbred BALB C; Moxifloxacin; Mycobacterium tuberculosis; Quinolines; Rifampin; Spleen; Treatment Outcome; Tuberculosis; Vaccines, DNA	2005
Efficient intermittent rifapentine-moxifloxacin-containing short-course regimen for treatment of tuberculosis in mice. Antimicrobial agents and chemotherapy, 2005, Volume: 49, Issue:10 Topics: Animals; Animals, Outbred Strains; Antibiotics, Antitubercular; Antitubercular Agents; Aza Compounds; Drug Therapy, Combination; Female; Fluoroquinolones; Mice; Moxifloxacin; Mycobacterium tuberculosis; Quinolines; Random Allocation; Rifampin; Survival Rate; Time Factors; Tuberculosis	2005
Hopkins scientist tunes in to treat tuberculosis. The Journal of clinical investigation, 2005, Volume: 115, Issue:12 Topics: Antitubercular Agents; Aza Compounds; Communicable Diseases; Drug Resistance; Fluoroquinolones; Humans; Moxifloxacin; Mycobacterium tuberculosis; Quinolines; Tuberculosis	2005
Combinations of R207910 with drugs used to treat multidrug-resistant tuberculosis have the potential to shorten treatment duration. Antimicrobial agents and chemotherapy, 2006, Volume: 50, Issue:11 Topics: Animals; Anti-Bacterial Agents; Antitubercular Agents; Aza Compounds; Colony Count, Microbial; Diarylquinolines; Drug Combinations; Drug Resistance, Multiple, Bacterial; Ethionamide; Fluoroquinolones; Lung; Mice; Moxifloxacin; Mycobacterium tuberculosis; Organ Size; Pyrazinamide; Quinolines; Rifampin; Spleen; Survival Analysis; Tuberculosis	2006
Drug combo speeds up TB treatment. AIDS patient care and STDs, 2007, Volume: 21, Issue:10 Topics: Antitubercular Agents; Aza Compounds; Clinical Trials as Topic; Fluoroquinolones; Humans; Moxifloxacin; Quinolines; Time Factors; Tuberculosis	2007
Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model. PLoS medicine, 2007, Volume: 4, Issue:12 Topics: Animals; Antibiotics, Antitubercular; Antitubercular Agents; Aza Compounds; Colony Count, Microbial; Disease Models, Animal; Drug Administration Schedule; Drug Therapy, Combination; Fluoroquinolones; Isoniazid; Lung; Mice; Mice, Inbred BALB C; Moxifloxacin; Mycobacterium tuberculosis; Pyrazinamide; Quinolines; Rifampin; Secondary Prevention; Time Factors; Tuberculosis	2007
Novel chemotherapy for tuberculosis: chemotherapeutic potential of econazole- and moxifloxacin-loaded PLG nanoparticles. International journal of antimicrobial agents, 2008, Volume: 31, Issue:2 Topics: Administration, Oral; Animals; Antitubercular Agents; Aza Compounds; Drug Carriers; Drug Compounding; Drug Delivery Systems; Drug Resistance, Multiple; Drug Therapy; Econazole; Fluoroquinolones; Lactic Acid; Moxifloxacin; Nanoparticles; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Polymers; Quinolines; Tuberculosis	2008
Promising results for new tuberculosis therapy. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2008, Jan-01, Volume: 178, Issue:1 Topics: Antitubercular Agents; Aza Compounds; Drug Therapy, Combination; Fluoroquinolones; Humans; Moxifloxacin; Quinolines; Tuberculosis	2008
Doctors report breakthrough antibiotic treatment for TB. The AIDS reader, 2007, Volume: 17, Issue:11 Topics: Animals; Antitubercular Agents; Aza Compounds; Clinical Trials as Topic; Drug Combinations; Fluoroquinolones; Humans; Mice; Moxifloxacin; Quinolines; Rifampin; Treatment Outcome; Tuberculosis	2007
Minimising moxifloxacin resistance with tuberculosis. The Lancet. Infectious diseases, 2008, Volume: 8, Issue:5 Topics: Antitubercular Agents; Aza Compounds; Colony Count, Microbial; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Quinolines; Sentinel Surveillance; Tuberculosis	2008
In vitro and in vivo activities of moxifloxacin and clinafloxacin against Mycobacterium tuberculosis. Antimicrobial agents and chemotherapy, 1998, Volume: 42, Issue:8 Topics: Animals; Anti-Infective Agents; Aza Compounds; Colony Count, Microbial; Female; Fluoroquinolones; Lung; Mice; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Organ Size; Quinolines; Quinolones; Spleen; Tuberculosis	1998
Effectiveness of once-weekly rifapentine and moxifloxacin regimens against Mycobacterium tuberculosis in mice. Antimicrobial agents and chemotherapy, 2001, Volume: 45, Issue:12 Topics: Animals; Anti-Bacterial Agents; Anti-Infective Agents; Antibiotics, Antitubercular; Antitubercular Agents; Aza Compounds; Colony Count, Microbial; Drug Resistance, Microbial; Female; Fluoroquinolones; Isoniazid; Lung; Mice; Moxifloxacin; Mycobacterium tuberculosis; Organ Size; Quinolines; Rifampin; Spleen; Streptomycin; Survival Rate; Tuberculosis	2001
In vitro and in vivo activities of gatifloxacin against Mycobacterium tuberculosis. Antimicrobial agents and chemotherapy, 2002, Volume: 46, Issue:4 Topics: Animals; Anti-Infective Agents; Antitubercular Agents; Aza Compounds; Colony Count, Microbial; Drug Combinations; Female; Fluoroquinolones; Gatifloxacin; Humans; Isoniazid; Mice; Mice, Inbred C57BL; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Nasal Cavity; Quinolines; Tuberculosis	2002
Bactericidal activity of increasing daily and weekly doses of moxifloxacin in murine tuberculosis. Antimicrobial agents and chemotherapy, 2002, Volume: 46, Issue:6 Topics: Animals; Anti-Infective Agents; Aza Compounds; Colony Count, Microbial; Female; Fluoroquinolones; Lung; Mice; Mice, Inbred BALB C; Moxifloxacin; Mycobacterium tuberculosis; Quinolines; Spleen; Survival Analysis; Tuberculosis	2002